Georgia Vogiatzi*, Antonios Pantazis and Dimitris Tousoulis Pages 2762 - 2768 ( 7 )
Cardiomyopathies are a heterogeneous group of heart muscle diseases and important cause of heart failure with reduced or preserved ejection fraction. Although there is an increasing body of evidence on the incidence, pathophysiology, and natural history of heart failure (HF) in cardiomyopathies, certain aspects of the therapeutic strategies remain unclear. More particularly, there is no consensus if to whether antithrombotic therapy has a favorable risk: benefit ratio in reducing thromboembolic event rate in patients with cardiomyopathies without suffering from primary valvular disease or atrial fibrillation. Although the observational data on increased venous thromboembolic risk are supported by multiple pathophysiological mechanisms, the role of antithrombotic therapy in these patients remains unclear. This review article provides an overview of epidemiologic, pathophysiologic, clinical, and therapeutic data for the prevention of thromboembolism in heart failure due to cardiomyopathies.
Cardiomyopathies, heart failure, antithrombotic, anticoagulation, anti-platelets, thromboembolism.
First Department of Cardiology, 'Hippokration' Hospital, National and Kapodistrian University of Athens Medical School, Athens, Inherited Cardiovascular Conditions Unit, Royal Brompton and Harefield Hospitals, London SW3 5UE, First Department of Cardiology, 'Hippokration' Hospital, National and Kapodistrian University of Athens Medical School, Athens